MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

Merck is targeting more than $70 billion in non-risk-adjusted pipeline opportunity by the mid-2030s as it prepares for Keytruda's 2028 loss of exclusivity, versus peak Keytruda consensus sales of $35 billion. Keytruda generated $16.40 billion in first-half 2026 revenue, up 4.2% year over year, while newer products Winrevair, Capvaxive and Welireg delivered $1.1 billion, $325 million and $470 million, respectively. The pipeline has nearly tripled since 2021 and Merck expects 20 launches by 2030, supplemented by acquisitions; however, 2026 EPS consensus has fallen to $2.97 from $3.76 over the past 60 days and the shares trade above industry and historical valuation multiples.

Analysis

MRK is increasingly being valued on a successful patent-cliff bridge rather than on its current earnings base, leaving little room for the ordinary delays, narrower labels, or slower payer uptake that characterize broad late-stage portfolios. The relevant underwriting question is not aggregate pipeline opportunity but the timing-adjusted revenue overlap: replacement franchises must scale before biosimilar erosion accelerates, while launch spending and acquired-asset integration pressure margins. Recent downward EPS revisions alongside a premium multiple make the next 1-3 months unusually sensitive to launch trajectory disclosures and 2027-28 guidance rather than to additional pipeline breadth.

AZN is the cleaner large-cap relative beneficiary from continued oncology share gains because Imfinzi's momentum can compound through label expansion without carrying the same single-product exclusivity overhang. BMY remains the weaker comparator: its mature immuno-oncology exposure offers less visible growth and makes it vulnerable to further multiple compression if replacement-product execution disappoints. A second-order positive for MRK is that successful commercialization of differentiated cardiopulmonary and infectious-disease assets would diversify its revenue duration; the contrarian view is that investors may be capitalizing management's non-risk-adjusted pipeline estimates too aggressively, effectively paying today for several independent clinical, regulatory, and reimbursement successes.

Over 6-18 months, MRK's principal catalyst is evidence that new-product growth offsets not merely revenue but the gross-profit contribution of its legacy oncology franchise. Falsification signals are a material deceleration in Winrevair demand, weaker persistence or reimbursement commentary, incremental EPS-guide cuts, or any evidence that biosimilar contracting begins earlier than modeled. The near-term stock move is likely asymmetric downward because valuation already embeds a relatively orderly transition, whereas a de-risked launch update has partly been anticipated after the recent outperformance.

Key Decisions for Investors

• Do not add outright MRK exposure at current premium valuation; maintain a watch position only and reassess after the next earnings release based on net-price, persistence, and full-year launch guidance. A further 2027 EPS-consensus decline or reduced new-product revenue outlook is the trigger for a tactical short.
• Express relative oncology strength through long AZN / short MRK over a 6-12 month horizon, sized beta-neutral. The thesis is multiple support from AZN's more diversified growth profile versus MRK's execution-dependent 2028 bridge; exit if AZN's oncology growth materially decelerates or MRK raises medium-term earnings guidance on demonstrated launch traction.
• For a defined-risk bearish MRK view into the next two earnings events, evaluate put spreads rather than outright puts only if implied volatility is below its pre-earnings range. Target a 2:1 payoff profile; the thesis is invalidated by a material upward revision to 2027-28 revenue or margin guidance.
• Avoid treating TERN or CDTX as standalone read-through longs without transaction-status, consideration, and closing-condition data. For merger-arbitrage monitoring, track regulatory clearance and closing timing; any residual spread should be evaluated against deal-specific break risk rather than MRK's portfolio narrative.